Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.34 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.34 |
| ▸ | TNF | P01375 | 5/20 | 0.33 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17811244 | 0.81 | CA2 (0.36) | CYP1A2ALDH1A1KMT2AMEN1PABPC1 | |
| SCHEMBL23479220 | 0.81 | CYP1A2 (0.37) | PDE3BPDE3ACYP1A2CYP2A6KMT2A | |
| SCHEMBL23478913 | 0.79 | PDGFRB (0.48) | KMT2AMEN1PABPC1EIF4HTRPV1 | |
| SCHEMBL21849067 | 0.77 | FGFR2 (0.45) | PDE3BPDE3AALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL14405531 | 0.77 | CYP1A2 (0.50) | PDE3BPDE3ACYP1A2CYP2A6KMT2A | |
| SCHEMBL4879213 | 0.76 | PDE3B (0.44) | PDE3BPDE3ACYP1A2CYP2A6ALDH1A1 | |
| SCHEMBL15043734 | 0.74 | RIPK2 (0.47) | CYP1A2ALDH1A1KMT2AMEN1PABPC1 | |
| SCHEMBL24721906 | 0.73 | GABRA1 (0.39) | KMT2AMEN1 | |
| SCHEMBL18318196 | 0.73 | SMN1; SMN2 (0.44) | PDE3BPDE3ACYP1A2CYP2A6HTT | |
| SCHEMBL15034693 | 0.73 | CYP1A2 (0.39) | PDE3BPDE3ACYP1A2CYP2A6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030853-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030853-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| US-11807641-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-11-07 | — | — | US | disclosed |
| US-11807641-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-11-07 | — | — | US | disclosed |
| US-11661418-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-05-30 | — | — | US | disclosed |
| US-11661418-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-05-30 | — | — | US | disclosed |
| US-20210179612-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2021-06-17 | — | — | US | disclosed |
| US-20210171461-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2021-06-10 | — | — | US | disclosed |
| US-20210171512-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2021-06-10 | — | — | US | disclosed |
| US-20210171531-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2021-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171531-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | PDE3B 2819/4885PDE3A 2618/4885CYP1A2 4271/4885 |
| US-11807641-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | PDE3B 2819/4885PDE3A 2618/4885CYP1A2 4271/4885 |
| US-20210179612-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | PDE3B 2819/4885PDE3A 2618/4885CYP1A2 4271/4885 |
| US-20210171512-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | PDE3B 2819/4885PDE3A 2618/4885CYP1A2 4271/4885 |
| US-12030853-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | PDE3B 2819/4885PDE3A 2618/4885CYP1A2 4271/4885 |
| US-11661418-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | PDE3B 2819/4885PDE3A 2618/4885CYP1A2 4271/4885 |
| US-20210171461-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | PDE3B 2819/4885PDE3A 2618/4885CYP1A2 4271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.